BioNxt Solutions Prepares for Human Bioequivalence Study For MS
23.4.2025 03:05:00 CEST | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment.
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish.
The Company plans to make further updates in the coming weeks regarding its bioequivalent study preparation and scheduling, as well integration of its research and development operations with Gen-Plus.
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X (OTCQB:KARX) to Present Global Growth Strategy and Showcase SkyXero at 26th MK-Equity Investment Conference in Munich25.9.2026 14:00:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / September 25, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a global carbon and environmental markets company, today announced that it will present at the 26th MK-Equity Investment Conference on September 30, 2026, in Munich, Germany. Chad Clovis, Chief Executive Officer, will present Karbon-X's equity story and global growth strategy to the conference audience. Investors and shareholders interested in connecting with Chad while he is in Munich are welcome to reach out to arrange a time to meet by contacting investors@karbon-x.com. The invitation-only conference is hosted by MK-Equity, the family office of Michael Kott. MK-Equity and Mr. Kott are significant investors in Karbon-X. The conference brings together family offices, high-net-worth individuals, active investors and entrepreneurs across a range of industries and is built around an ecosystem of like-minded investors focused on the intersection of people and megatrends. During
Fermi Selects CBRE to Operate and Maintain Its First Data Center24.9.2026 22:01:00 CEST | Press release
DALLAS, TX / ACCESS Newswire / September 24, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced today that its subsidiary, Fermi Services LLC, has signed a management agreement with CBRE, the world's largest commercial real estate services firm and provider of critical infrastructure services. CBRE will be the exclusive operations and maintenance provider for building one, Fermi's first data center in the Texas Panhandle. It runs five years from the day building one is first ready for service, and Fermi can renew it in five-year terms. "We're locking in proven partners early to make our operations and construction activities as safe and efficient as possible," said Lee McIntire, Fermi Chief Executive Officer. "CBRE runs some of the most demanding data center environments in the world. Bringing them in now means that when building one is ready for service, the people, the programs, and the procedures to run it are already in plac
LiberNovo Opens Business & Bulk Ordering Ahead of Its Fall Prime Sale24.9.2026 06:50:00 CEST | Press release
HONG KONG, HK / ACCESS Newswire / September 24, 2026 / LiberNovo has opened its Business & Bulk Orders section ahead of the Fall Prime Sale, which runs at eu.libernovo.com and uk.libernovo.com. Team ordering goes live on 23 September, and seasonal sale pricing opens 30 September, with a flash sale on selected products on 6-7 October. Discounts reach up to 39% off, and every order is covered by 30-Day Price Protection. Ordering for a team, not a desk Business & Bulk Orders is live from today, covering orders of five chairs or more across the Omni and Maxis series - chairs alone or paired with a footrest - with tiered pricing at five to ten units and again at eleven or more. Discount rates and how they combine with the rest of the sale are set out on each regional page. The timing follows how companies buy: budgets close in the autumn, workstations get specified for the year ahead, and wellbeing programmes are agreed before January. Why October October is National Ergonomics Month. Hybri
OMP and PwC Alliance Moves Process Manufacturers from Siloed Supply Chain Planning to Unified Decisions23.9.2026 14:25:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / September 23, 2026 / OMP and PwC have formed an alliance to bring unified, faster supply chain decisions to process manufacturers in life sciences, consumer goods, and chemicals. Planning in these industries runs on campaign production, long lead times, and regulatory requirements, all surfacing "too late to act on" when planning sits in separate systems. The alliance combines Unison Planning™, OMP's AI-enabled planning platform with built-in industry expertise, and PwC's implementation services. German specialty pharmaceutical company medac is already live under the alliance, with its planners working on a single demand plan in Unison Planning™. PwC and medac will present the project on October 15, 2026, at the OMP Conference in Singapore, detailing the approach behind the rollout and what it means for planning in pharma. Combining innovation, industry knowledge, and integration OMP and PwC run each implementation as a single program. OMP brings Uniso
SmartVendor Brings Autonomous Retail to the Czech Parliament; Clears Europe's Toughest Privacy Bar with SHEKEL WeightAI(TM)23.9.2026 11:20:00 CEST | Press release
PRAGUE, CZ / ACCESS Newswire / September 23, 2026 / SmartVendor today announced the deployment of an autonomous, AI-powered retail solution inside the Chamber of Deputies of the Parliament of the Czech Republic, built on the WeightAI™ platform from SHEKEL Scales Ltd., the weight-based AI technology and solution provider behind the next generation of autonomous retail. For public institutions across Europe, autonomous retail has presented a compliance contradiction: the technology that makes unattended stores work typically relies on cameras, and cameras mean GDPR risk. The Czech Parliament resolved that contradiction by choosing a solution built on WeightAI™. No cameras. No biometrics. No personal data captured at the point of purchase. Full GDPR compliance by design. The installation, deployed by SmartVendor on the Innovendi Elite platform, marks one of the first deployments of an autonomous AI-powered retail solution inside a major state institution in the Czech Republic. Members of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom